Use of rituximab plus lenalidomide for the treatment of follicular lymphoma in Ontario, Canada

Summary

Client: Hoffmann-La Roche Limited

Project ID: P2023-203/ 2025 0970 389 000

Research Question/Objectives: How many follicular lymphoma (FL) patients have received R-Len (Rituximab plus lenalidomide combination), year-over-year, between 2018 and 2023?

Objectives:

• The aims for this analysis are to identify FL patients receiving this R-Len regimen in the linked data.

Status: Completed

Results: July 2025